CryoPort (OTCBB: CYRX) Now Fully Integrated into DHL Ordering System for Frozen Shipments

CryoPort Inc. (OTCBB: CYRX), a provider of cold chain frozen shipping systems, in partnership with FedEx (NYSE: FDX) and other companies similar to United Parcel Service Inc. (NYSE: UPS), is now fully integrated into DHL's ordering system for frozen shipments.

CryoPort, Inc. (OTCBB: CYRX) today announced that it has completed the integration of its sophisticated order entry and tracking web portal with DHL's ordering and billing systems. DHL's life science customers around the world can now order directly from CryoPort and receive preferred DHL shipping rates.

"We are very pleased that DHL is offering its customers direct access to the CryoPort Express® Dry Shipper through our fully integrated, easy-to-use ordering system," said Larry Stambaugh, CryoPort's Chairman and Chief Executive Officer. "Because the CryoPort Express system is an end-to-end solution, DHL customers can prepare a complete shipment order in six simple steps on our portal. Our current customers tell us that the speed and convenience of our service allows them to spend more time on their business and less on paperwork and packaging."

The reusable CryoPort Express Dry Shipper is designed to meet the needs of clinical labs, diagnostic companies, research organizations, and the biotech and pharmaceutical industries by allowing tissue samples, blood and other biological material to remain frozen at or below -150C for 10+ days, in contrast to the current industry practice of dry-ice packaging, which often requires re-icing during transit.

About CryoPort, Inc.

CryoPort (www.cryoport.com) has developed a leading edge, proprietary, technology-driven transport and packaging system focused on providing a solution that replaces dry ice for the frozen shipping market in the growing global life science industry. The products developed by CryoPort have a 10+ day holding time, are using "green" materials and are essential components of the infrastructure required for the testing, research and end-user delivery of temperature-sensitive medicines and biomaterials in an increasingly complex global logistical environment.

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.